MF
Mark Feitelson
Principal Investigator
SFA Therapeutics
I'm working on
7 months ago
A new therapeutic approach to autoimmune diseases
About
The issued patent was published in September, 2023. This is a composition of matter patent for multiple autoimmune diseases including inflammatory skin diseases.
Partnering listings
Learn more
SFA Therapeutics
Development of short chain fatty acid based therapeutics targeting chronic inflammatory diseases (cancer, autoimmunity, neurodegeneration)
We have developed short chain fatty acid (SCFA) formulations that have successfully targeted chronic inflammatory conditions by epigenetic mechanisms that restore homeostasis and health by immunomodulation instead of imm...
TechnologyConceptualCompany
SFA Therapeutics
Microbial metabolites against chronic inflammatory diseases: cancer, autoimmunity and neurodegeneration
We have developed selective gut microbial metabolites into drugs and are effective against the development of inflammation associated cancer in preclinical animal models and against autoimmune disease in a human clinical...
TechnologyConceptualCompany
SFA Therapeutics
Therapeutic bacterial metabolites as natural GLP-1 agonists
Development of a safe, oral therapeutic using bacterial metabolites that act as natural GLP-1 agonists to reduce weight. Proven efficacy in mice with potential for human application. Seeking partners for research sponsor...
TechnologyConceptualCompany
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.